Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Public ClinicalTrials.gov record NCT03828019. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-tumor necrosis(TNF)-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
Study identification
- NCT ID
- NCT03828019
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 227 participants
Conditions and interventions
Conditions
Interventions
- Adalimumab (ADA) Biological
- Conventional immunosuppression (CON) Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2019 (Actual)
- Primary completion
- Apr 2, 2024 (Actual)
- Completion
- Sep 9, 2024 (Actual)
- Last update posted
- May 16, 2025
2019 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Jules Stein Eye Institute, UCLA | Los Angeles | California | 90095 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| National Eye Institute | Bethesda | Maryland | 20892 | — |
| Ophthalmic Consultants of Boston | Boston | Massachusetts | 02114 | — |
| University of Michigan Health System, Kellogg Eye Center | Ann Arbor | Michigan | 48105 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| MidAtlantic Retina, Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Tennessee Retina | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Eye Institute | Nashville | Tennessee | 37232 | — |
| Retinal Consultants of Texas | Bellaire | Texas | 77401 | — |
| University of Utah, Moran Eye Center | Salt Lake City | Utah | 84132 | — |
| University of Washington, Medicine Eye Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03828019, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2025 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03828019 live on ClinicalTrials.gov.